1. Beating Hematological Neoplasms
   Yoshihiro Hatta, 2023, Journal of Nihon University Medical Association CrossRef
2. Cutaneous Leukemic Infiltrates Successfully Treated With Biomodulatory Therapy in a Rare Case of Therapy-Related High Risk MDS/AML
   Daniel Heudobler et al, 2018, Frontiers in Pharmacology CrossRef
3. Tumor cell derived osteopontin and prostaglandin E2 synergistically promote the expansion of myeloid derived suppressor cells during the tumor immune escape phase
   Doste R Mamand et al, 2024, International Immunopharmacology CrossRef
4. PPAR-γ Modulators as Current and Potential Cancer Treatments
   Tiange Chi et al, 2021, Frontiers in Oncology CrossRef
5. Role of PPAR Receptor and Ligands in the Pathogenesis and Therapy of Hematologic Malignancies
   Jian Wu et al, 2022, Hemato CrossRef
6. CRISPR/Cas9 technology: A promising gene-editing tool for the treatment of cancers
   Muhammad Khairi Ahmad et al, 2023, Iranian Journal of Blood and Cancer CrossRef
7. Alteration of PPAR‐GAMMA (PPARG; PPARγ) and PTEN gene expression in acute myeloid leukemia patients and the promising anticancer effects of PPARγ stimulation using pioglitazone on AML cells
   Shadi Esmaeili et al, 2021, Molecular Genetics & Genomic Medicine CrossRef
8. New Inhibitor Targeting Signal Transducer and Activator of Transcription 5 (STAT5) Signaling in Myeloid Leukemias
   Ludovic Juen et al, 2017, Journal of Medicinal Chemistry CrossRef
9. Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic Drugs
   Panagiota Papanagnou et al, 2016, Pharmaceuticals CrossRef